Department of Health written question – answered on 26th May 2016.

Alert me about debates like this

Photo of Dan Jarvis Dan Jarvis Labour, Barnsley Central

To ask the Secretary of State for Health, what assessment his Department has made of the effect of the Cystic Fibrosis Trust's proposal for collaboration between the NHS and Vertex to widen access to the treatment Orkambi on the treatment of the patients with that disease.

Photo of George Freeman George Freeman The Parliamentary Under-Secretary of State for Business, Innovation and Skills, The Parliamentary Under-Secretary of State for Health

The Department has received the Cystic Fibrosis Trust’s proposals for an arrangement that would potentially allow access to Orkambi (lumacaftor in combination with ivacaftor) as part of a Managed Access Scheme in the National Institute for Health and Care Excellence’s (NICE) appraisal of Orkambi.

I have encouraged the Trust and the manufacturer, Vertex Pharmaceuticals, to engage with NICE to consider whether there remains scope for this, or any other, proposal to be taken into account in its appraisal and the Department is also engaging with the manufacturer directly on this matter.

Does this answer the above question?

Yes1 person thinks so

No0 people think not

Would you like to ask a question like this yourself? Use our Freedom of Information site.